Talquetamab, a bispecific IgG4 antibody that binds to both GPRC5d and CD3 to induce killing of GPRC5d-expressing myeloma cells by means of T-cell-mediated cytotoxicity (51, 52). The gene discussed is GPRC5D; the disease is plasma cell myeloma.